These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8245524)

  • 1. Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines.
    De Santis C; Robbioni P; Longhi R; Lopalco L; Siccardi AG; Beretta A; Roberts NJ
    J Infect Dis; 1993 Dec; 168(6):1396-403. PubMed ID: 8245524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
    Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
    AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Frey SE; Newman FK; Belshe RB
    J Clin Microbiol; 1992 Oct; 30(10):2606-12. PubMed ID: 1400960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    Graham BS; Matthews TJ; Belshe RB; Clements ML; Dolin R; Wright PF; Gorse GJ; Schwartz DH; Keefer MC; Bolognesi DP
    J Infect Dis; 1993 Mar; 167(3):533-7. PubMed ID: 8095059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Frey SE; Patel G; Newman FK; Belshe RB
    Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells.
    de Santis C; Lopalco L; Robbioni P; Longhi R; Rappocciolo G; Siccardi AG; Beretta A
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):157-62. PubMed ID: 7515259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine.
    Haubrich RH; Takeda A; Koff W; Smith G; Ennis FA
    J Infect Dis; 1992 Mar; 165(3):545-8. PubMed ID: 1538159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
    Parry C; McLain L; Dimmock NJ
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.
    Salmon-Céron D; Excler JL; Sicard D; Blanche P; Finkielstzjen L; Gluckman JC; Autran B; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Dec; 11(12):1479-86. PubMed ID: 8679292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Newman FK; Belshe RB; Berman PW; Gregory TJ; Matthews TJ
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):378-86. PubMed ID: 8807200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
    Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
    J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.
    Sitz KV; Ratto-Kim S; Hodgkins AS; Robb ML; Birx DL
    J Infect Dis; 1999 Apr; 179(4):817-24. PubMed ID: 10068576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
    Belshe RB; Clements ML; Dolin R; Graham BS; McElrath J; Gorse GJ; Schwartz D; Keefer MC; Wright P; Corey L
    J Infect Dis; 1993 Dec; 168(6):1387-95. PubMed ID: 8245523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients.
    Funkhouser A; Clements ML; Slome S; Clayman B; Viscidi R
    AIDS Res Hum Retroviruses; 1993 Jul; 9(7):627-32. PubMed ID: 8369168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.